摘要
恶性脑胶质瘤全球发病率为3.20/100,000,患者中位生存期不足2年,5年生存率仅9.8%,治疗后复发率几近100%,且目前仍无有效治疗方案。由于恶性胶质瘤存在浸润性生长的特点,手术无法根治,对于常用化疗药物又普遍存在内在抗拒性,导致化疗疗效有限。由于血脑屏障的存在,几乎全部的大分子药物以及98%以上的小分子药物都无法到达病灶,而受体介导的转运方式利用了血脑屏障自身的特性,通过内源性血脑屏障转运系统有效的跨越血脑屏障并靶向恶性胶质瘤进行药物输送,为胶质瘤的治疗提供了一种更为安全且有效的递药策略。
The worldwide cancer incidence of malignant encephalic glioma is 3.20/100,000, the median survival for patients is less than 2 years and 9.8% of patients survived five years post diagnosis, with near 100% relapse rates and currently limited treatment options. Operations and chemotherapy drugs have limited efficacy for aggressive glioma with intrinsic resistance to drugs. Almost the whole of macromolecule and 98% of small-molecule drugs are unable to across blood-brain barrier. The receptor mediated endocytosis is one of the endogenous transporting channels, xenobiotics across blood-brain barrier and target glioma by taking advantages of cells. It provides a safer and more effective drugs delivery strategy for cancer treatment.
出处
《药物资讯》
2018年第2期27-32,共6页
Pharmacy Information
基金
Tfr抗体介导的海藻活性组分的抗脑胶质瘤活性及机制研究(SQ2017JSKF0027)-海南省创新能力建设计划(省属科研院所技术开发专项)。
